Rare cancers account for ~25–30% of all cancer diagnoses and 25% of cancer deaths, representing a substantial burden of disease. However, basic science research, clinical trials and approval of new therapies for rare cancers are lacking. This translates into a worse prognosis for patients with a rare cancer than for those with common cancers. With the number of rare cancers increasing, finding more appropriate solutions for diagnosing, managing and studying rare cancers is essential.
EBioMedicine journal’s website https://www.ebiomedicine.com/article/S2352-3964(19)30601-2/fulltext and ScienceDirect https://www.sciencedirect.com/science/article/pii/S2352396419306012.